Maryam Ghasemi-Kasman Selected Research

Arbutin

11/2019	Arbutin reduces cognitive deficit and oxidative stress in animal model of Alzheimer's disease.
1/2019	Arbutin attenuates cognitive impairment and inflammatory response in pentylenetetrazol-induced kindling model of epilepsy.
11/2018	Arbutin attenuates behavioral impairment and oxidative stress in an animal model of Parkinson's disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maryam Ghasemi-Kasman Research Topics

Disease

11	Demyelinating Diseases (Demyelinating Disease) 03/2022 - 01/2017
8	Epilepsy (Aura) 01/2021 - 01/2017
7	Multiple Sclerosis 03/2022 - 01/2017
3	Inflammation (Inflammations) 03/2022 - 01/2018
3	Alzheimer Disease (Alzheimer's Disease) 11/2020 - 01/2019
3	Seizures (Absence Seizure) 01/2019 - 01/2017
2	Memory Disorders (Memory Loss) 01/2022 - 10/2017
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020 - 07/2018
2	Parkinson Disease (Parkinson's Disease) 01/2019 - 11/2018
2	Neoplasms (Cancer) 01/2019 - 01/2017
2	Nervous System Diseases (Neurological Disorders) 01/2019 - 01/2018
2	Cognitive Dysfunction 01/2019 - 10/2017
1	Coronary Artery Disease (Coronary Atherosclerosis) 08/2021
1	COVID-19 12/2020
1	Autistic Disorder (Autism) 11/2020
1	Relapsing-Remitting Multiple Sclerosis 01/2020
1	Infections 01/2020
1	Schizophrenia (Dementia Praecox) 01/2020
1	Teratoma (Teratoid Tumor) 01/2020
1	Huntington Disease (Huntington's Disease) 01/2019
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2019
1	Central Nervous System Diseases (CNS Diseases) 01/2019
1	Weight Loss (Weight Reduction) 12/2017
1	Carcinoma (Carcinomatosis) 01/2017

Drug/Important Bio-Agent (IBA)

9	Lysophosphatidylcholines (Lysophosphatidylcholine)IBA 03/2022 - 01/2017
5	CurcuminIBA 01/2019 - 01/2017
4	Fingolimod Hydrochloride (FTY720)FDA Link 03/2022 - 01/2017
4	Pentylenetetrazole (Metrazol)IBA 01/2019 - 01/2017
3	ArbutinIBA 11/2019 - 11/2018
3	QuercetinIBA 01/2019 - 05/2018
3	ChitosanIBA 02/2018 - 01/2017
2	hesperetinIBA 11/2020 - 08/2018
2	Valproic Acid (Depakote)FDA LinkGeneric 11/2019 - 01/2018
2	AlginatesIBA 10/2017 - 01/2017
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Biological ProductsIBA 01/2022
1	MicroRNAs (MicroRNA)IBA 01/2022
1	Diethylhexyl Phthalate (DEHP)IBA 01/2022
1	Cyclin-Dependent Kinase Inhibitor p16IBA 08/2021
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2021
1	InflammasomesIBA 01/2021
1	EndocannabinoidsIBA 01/2021
1	FlavonoidsIBA 11/2020
1	Immunologic Factors (Immunomodulators)IBA 01/2020
1	LipopolysaccharidesIBA 01/2020
1	Sphingosine-1-Phosphate ReceptorsIBA 01/2020
1	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 01/2020
1	ZincIBA 01/2020
1	Histone Deacetylase InhibitorsIBA 11/2019
1	AntioxidantsIBA 01/2019
1	acetonitrileIBA 01/2019
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2019
1	Pharmaceutical PreparationsIBA 01/2019
1	Conditioned Culture MediaIBA 01/2019
1	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 11/2018
1	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 07/2018
1	5- amino- 7- (2- phenylethyl)- 2- (2- furyl)pyrazolo(4,3- e)- 1,2,4- triazolo(1,5- c)pyrimidineIBA 07/2018
1	Purinergic P1 Receptors (Adenosine Receptor)IBA 07/2018
1	triphosphoric acid (triphosphate)IBA 02/2018
1	piperineIBA 02/2018
1	Hematoxylin (Haematoxylon)IBA 01/2018
1	Neuroprotective AgentsIBA 01/2018
1	CuprizoneIBA 01/2018
1	Erythropoietin FDA Link 01/2018
1	Eosine Yellowish-(YS) (Eosin)IBA 01/2018
1	gamma-Globulins (gamma-Globulin)IBA 12/2017
1	Alkaline PhosphataseIBA 12/2017
1	Proteins (Proteins, Gene)FDA Link 12/2017
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 12/2017
1	Blood Proteins (Serum Proteins)IBA 12/2017
1	Anticonvulsants (Antiepileptic Drugs)IBA 10/2017
1	Pregabalin (Lyrica)FDA Link 01/2017

Therapy/Procedure

7	Therapeutics 01/2021 - 01/2017
1	Oral Administration 03/2022
1	Intranasal Administration 03/2022
1	Intraperitoneal Injections 01/2019
1	Phytotherapy (Herbal Therapy) 11/2018
1	Aftercare (After-Treatment) 12/2017